Clincosm LogoSign in Get a demo

telomereFL: Telomere Parameters in Patients With Nonalcoholic Fatty Liver

Sponsor
Meir Medical Center (Other)
Overall Status
Unknown status
CT.gov ID
NCT01694342
Collaborator
(none)
30
Enrollment
1
Location

Study Details

Study Description

Brief Summary

Telomerase, through its regulatory function on telomere length may play an important role in immune function, cellular replicative life span, and carcinogenesis. Non-alcoholic fatty liver disease (NAFLD) is considered a benign condition, but in some cases, it may progress to cirrhosis and hepatocellular carcinoma. The risk factors for that evolution are not fully understood.

Our group showed in a previous study, that hTERT mRNA expression is lower in peripheral lymphocytes of patients with fatty liver, compared to healthy controls. This finding could explain the telomere shortening found previously in these patients by our group [20] and others [21]. Furthermore, we found higher rates of TC in these patients, probably due to an attempt to counteract the shortening of the telomeres and to stabilize them. This is through a different mechanism that is not telomerase-mediated.

Telomere capture is considered an alternative way to maintain telomere length and chromosomal stability [3]. It is a more common mechanism for chromosome stabilization and repair, in contrast to the telomerase-mediated process of chromosome healing and elongation This study aimed to evaluate mechanisms of telomere homeostasis like telomere shortening, telomerase activity, telomere capture and aneuploidy in patients with NAFLD in order to explain previous findings of telomere shortening in these patients.

Condition or Disease Intervention/Treatment Phase

    Study Design

    Study Type:
    Observational
    Anticipated Enrollment :
    30 participants
    Observational Model:
    Cohort
    Time Perspective:
    Prospective
    Official Title:
    Telomere Parameters Like Telomere Length, Telomerase Expression, Telomere Capture and Aneuploidy in Patients With Nonalcoholic Fatty Liver
    Study Start Date :
    Sep 1, 2012

    Outcome Measures

    Primary Outcome Measures

      Eligibility Criteria

      Criteria

      Ages Eligible for Study:
      18 Years to 75 Years
      Sexes Eligible for Study:
      All
      Accepts Healthy Volunteers:
      Yes
      Inclusion Criteria:

      • age over 18

      • diagnosis of fatty liver

      Exclusion Criteria:

      • no malignancy

      • no eligible to sign the consent paper

      Contacts and Locations

      Locations

      Site City State Country Postal Code
      1 Meir Hospital Kefar Saba Israel

      Sponsors and Collaborators

      • Meir Medical Center

      Investigators

      None specified.

      Study Documents (Full-Text)

      None provided.

      More Information

      Publications

      None provided.
      Responsible Party:
      Meir Medical Center
      ClinicalTrials.gov Identifier:
      NCT01694342
      Other Study ID Numbers:
      • ramona 1.0
      First Posted:
      Sep 27, 2012
      Last Update Posted:
      Sep 27, 2012
      Last Verified:
      Jul 1, 2012
      Additional relevant MeSH terms:
      Fatty Liver
      Non-alcoholic Fatty Liver Disease

      Study Results

      No Results Posted as of Sep 27, 2012